Applications Are Now Open!
Abstract applications are now OPEN for Advances in IBD 2023, which will be held at the Walt Disney World Dolphin Hotel from December 14-16, 2023.
Your comprehensive poster abstract proposal(s) MUST be submitted by Monday, September 18, 2023 at 11:59 PM ET to be considered for acceptance at this year's event. Abstracts are subject to acceptance by the Scientific Review Committee. Accepted abstracts will be published in the American Journal of Gastroenterology and accepted for poster display at the 2023 AIBD conference. Only abstracts received by the submission deadline will be considered. Acceptance notifications will be sent on or before October 30, 2023.
Abstracts will be accepted in the following categories: CLINICAL, SURGERY, PEDIATRIC, NURSING/APP, or YOUNG INVESTIGATOR. Please indicate which category is appropriate by checking the appropriate box in the online submission system.
CLINICAL ABSTRACT CATEGORIES
- Outcomes Research
- Clinical Trials and IBD Therapies
- Procedures and Diagnostics
- Case Reports
SURGERY CLINICAL ABSTRACT CATEGORIES
PEDIATRIC CLINICAL ABSTRACT CATEGORIES
NURSING/APP CLINICAL ABSTRACT CATEGORIES
- Nurses/Advanced Practice Providers
YOUNG INVESTIGATOR CLINICAL ABSTRACT CATEGORIES
- Young Investigator
- Abstracts must be in English
- 504-word count limit (additional 4 words allows for inclusion of tiles for each section - i.e. Background, Methods, Results, and Conclusion(s))
- Use a concise title in title case only. (Example: This is the Title of my Presentation)
- Provide names and affiliations of ALL author(s)
- Use standard and well-accepted abbreviations
- References do not need to be submitted in the Abstract. Please include them in the final poster.
- Abstract content should be single-spaced and typed in lower case; abstract title should not include any formatting
- Abstracts shall be of original research and contain a concise statement of study aim
- No uploaded tables or graphs shall be included in submitted abstract
- Please include the following four (4) parts of your abstract: Background, Methods, Results, and Conclusion(s). Conclusions must be supported by your results and summarized within your abstract at the time of submission. Results “to be completed” and/or conclusions “to be discussed” are not acceptable
Previous Presentation, Publication and Duplication of Abstracts
- Encore abstracts will be allowed if they contain new data. During the submission process you will be asked if the abstract has been presented before, when you say yes you will be prompted to submit the original abstract as a reference
- Abstracts will not be considered for presentation if they have been or will be published as an article (includes manuscripts accepted for publication) in either printed or electronic format upon the abstract submission deadline
- Abstracts will not be considered for presentation if they have been duplicated in any way
- Abstracts may not be submitted to more than one category
- Abstracts that have been submitted to the Advances in IBD Conference in previous years, and have not been accepted for poster presentation, are eligible for submission but must contain new, additional information to be considered
- Violations of these policies could result in a sanction from submitting abstracts to this conference for the submitting author
Poster Abstract Awards
Abstracts are reviewed and accepted by the AIBD Scientific Review Committee. Each year the AIBD Scientific Review Committee recognizes the “Best Of” submitted abstracts. Winning abstracts receive free conference registration and a $500 scholarship to help off-set associated travel expenses. Abstract awards are given for the following categories: Clinical, Surgery, Pediatric, Nursing/APP, and Young Investigator.
Submission of an abstract constitutes a commitment by the author(s) to 1) submit an appropriately formatted abstract poster to showcase in the AIBD poster hall, and 2) conduct an oral presentation if selected as the winning abstract for the category (i.e., Best of Surgery Abstract). Failure to present, if not justified, will jeopardize acceptance of future abstract submissions. Only the primary author or co-author may present the accepted abstract at the 2022 Advances in IBD Conference.
The conference will withdraw abstracts upon written notification from the submitting author by October 15, 2022. Acceptance of the abstract obligates the author to present the paper.
Industry authors can be a co-author, but they cannot be the lead and/or senior author. Further, Industry authors cannot be the ones to present the research on site at AIBD. There are absolutely no exceptions to this rule.
Printed Poster Guidelines
All accepted posters are expected to be present on-site at Advances in IBD 2023, which will be held at the Walt Disney World Dolphin Hotel from December 14-16, 2023. Poster abstracts will be made available to attendees via the conference app, but no virtual versions of posters will be presented.
- Poster boards will be 6ft wide by 4ft tall. Please ensure your printed poster is no larger than these dimensions.
- Please secure your poster to the poster board using provided thumbtacks. Limited supply will be on site for each poster, so we recommend bringing more if you need it.
Q: Where do I submit a virtual version of my poster?
A: Due to being a fully live conference, we will not utilize virtual versions of posters. Simply bring your physical poster with you on site to Orlando. Accepted abstracts will be available for attendees to view in our Conference App, but you do not need to provide anything to us prior to being on site.
Q: If I cannot attend the live meeting in Orlando, will my abstract still be published in ACG and the Conference App?
A: Yes, by being accepted, your abstract will automatically be published in ACG’s journal supplement as well as be available to attendees via our Conference App.
Q: I cannot attend the conference, but a fellow author wants to attend and present in my place. Is this possible?
A: Per to our guidelines, co-authors may present the poster on site at AIBD. However, no one from industry (even if a co-author) is allowed to present research on site at AIBD.
Q: I have more information I’d like to provide with attendees that won’t fit on my poster. Can I provide handouts?
A: Rather than providing handouts on site, we recommend adding a QR code to your poster that links to the additional information.
Q: Am I able to print my poster on site?
A: AIBD does not offer printing services onsite for posters. We strongly recommend finding a printing center that can print your poster for you prior to arriving onsite.
Q: Is there a template I need to use to design my poster?
A: There is no required template for posters. As long as your poster fits within the provided sizing guidelines, feel free to design your posters however you would like!
Q: How will I know when I need to present my poster?
A: Posters will be hung while the Exhibit Hall is open. Specific set up and tear down times will be provided to accepted poster presenters via email. We recommend standing by your poster during the Opening Reception and during Exhibit Hall breaks, but formal presentation times are not required.
Q: Do I need to register for the conference after being accepted?
A: Yes, you must register in order to present a poster at AIBD. Please refer to our rates page for more information.
Do you have a question that is not answered above? Please contact Kathleen Krause at firstname.lastname@example.org.
Congratulations to the 2022 Poster Award Winners!
Best of 2022 AIBD Abstract in Pediatrics
Changing Use of Biologic Medications and Associated Outcomes for Pediatric Inflammatory Bowel Disease
Jeremy Adler, MD
Best of 2022 AIBD Clinical Abstract from a Young Investigator
Development of an Artificial Intelligence Tool for Detection of Polypoid Lesions in Inflammatory Bowel Disease (IBD-CADe)
Daniela Guerrero Vinsard, MD
Best of 2022 AIBD Abstract in Surgery
Transanal Ileal Pouch-anal Anastomosis for Inflammatory Bowel Disease (ta-IPAA): A Systematic Review and Meta-analysis
Eddy Lincango, MD
Best of 2022 AIBD Clinical Abstract
Venous Thromboembolism Risk in Hospitalized Tofacitinib-Exposed Patients: A Real-World Experience of 533 Patients
Megan Obi, MD